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Abstract
Nail apparatus melanoma (NAM) is a rare dermatologic malignancy. Its prognosis is poor because 
it is often diagnosed late. However, progression and survival of NAM patients have only been 
studied among small populations. Early biopsy could help to identify suspicious lesions at a less 
invasive stage. While surgery is generally seen as the treatment of choice, the extent of excision 
margins and the use of sentinel biopsy remain debated. This systematic review aims to summarize 
the treatment procedures and observed prognosis in the literature during the last two decades and 
present pooled survival and progression rates of NAM by using meta-analysis. A systematic 
review on studies assessing pathology, treatment and prognosis of NAM was carried out up to end 
of 2018. After evaluation of eligible studies, the main emerging topics were outlined and pooled 
survival outcomes estimated. A total of 30 articles out of 624 identified records were included for 
systematic review. Finally, meta-analysis of pooled mortality rates including 18 studies was 4.6 x 
100 patent-years (95% CI: 2.7, 6.8) equivalent to 5-year cumulative survival of 77.0%. 
Additionally, the pooled progression rate based on 17 studies was 6.3 x 100 patent-years (95% CI: 
4.1, 8.9) with estimated 5-year cumulative progression-free survival of 68.5%.While the optimal 
extent of surgical treatment remains debated, prompt biopsy could help to identify early lesions. 
This is the first study to present pooled survival and progression rates by meta-analysis.
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Introduction
Nail apparatus melanoma (NAM) is an infrequent subtype of cutaneous melanoma, that originates 
from the nail. 1–5 The epidemiology of NAM varies among ethnicities, with incidence rates from 
0.31-1.5% in Caucasian populations,6,7 and with a relative frequency of up to 20%  among all 
melanomas in Africans and Asians.8,9 An incidence peak is observed around the sixth life 
decade,6,10 even though single paediatric cases have also been described.11–13
The aetiology of the disease remains inconclusive. Many factors such as the role of trauma, 
exposure to UV-light or family history have been discussed in the literature with conflicting 
results.6,14–18 NAM shows a poorer prognosis than other melanomas. The causative role of a more 
aggressive tumour behaviour had long been a widely accepted opinion.19–22 However, delay in 
diagnosis due to late presentation of the patients, insufficient biopsy material or misdiagnosis, 
especially in early disease stages, were recently discussed.4,9,23–27 
Due to its bad prognostic reputation, amputation of the affected (part of the) digit has been a 
commonly accepted approach.28–30 Lately, more conservative surgical treatments were used with 
no difference concerning survival outcome but superior results regarding functionality and 
cosmesis, thus resulting in a better quality of life.29,31
However, up to date only small population studies about the outcome of NAM have been 
performed given the rarity of the disease. To our knowledge, this study is the first to present 
pooled survival and progression rates of NAM by using meta-analysis. 
Methods Systematic review
Search strategy
This systematic review including meta-analysis was performed following the PRISMA guidelines. 
A literature search was conducted in Ovid MEDLINE and Scopus from January 2000 to 
December 2018. The following search terms, their synonyms or respective combinations were 
applied: subungual, nail apparatus, nail bed, nail matrix, melanoma, cancer and neoplasm. The 
search strategy was validated by the inclusion of two key articles (Ogata et al., 32 Tan et al.10) 
known by the authors to fit the field of the systematic review. The final search string can be found 










This article is protected by copyright. All rights reserved
Initial results were exported from the databases into an Excel file (Microsoft) and selection 
decisions documented therein. The result lists were merged and duplicates eliminated. Title, 
abstracts and publication type were screened for inclusion in full-text assessment. Criteria leading 
to study exclusion were language other than English, French or German, letters, comments, non-
human or ex-vivo studies, reviews and case reports with less than two cases. No geographical 
restrictions were applied.
Full-text assessment of all available articles was performed by applying inclusion and exclusion 
criteria. Included studies reported both histopathologic (tumor thickness and/or stage) and 
prognostic data (follow-up and outcome) on nail apparatus melanoma (NAM). NAM was defined 
as melanoma of the nail bed, matrix or periungual skin. Outcome was defined as death or 
recurrence. Publications without differentiation between NAM and other tumors of the nail 
apparatus or melanoma at different sites were excluded.
Data collection
After evaluation of all selected studies, data from each publication was extracted and subclassified 
including year of publication, time period, number of patients, age, gender distribution, tumor site, 
tumor thickness, tumor stage, number of sentinel lymph node biopsies (SLNB), type of surgery, 
follow-up time, number of recurrence and number of death (Table 1). Finally, the essential topics 
from the papers were discussed in more detail and a meta-analysis of recurrence and survival rates 
performed. 
Statistical analysis
In order to pool survival outcomes across different studies, a meta-analysis was conducted by 
including studies with at least 10 patients with available follow-up data and with a mean age of 50 
years or more.
More specifically, the incidence rate of both overall death and NAM progression was estimated by 
considering the number of reported events at the numerator and the total person-time at the 
denominator. Person-time was calculated as the time, in years, from baseline since last visit or first 
recorded event and estimated from the reported mean total follow-up time and mean time to 
progression. When only the median follow-up time was available, it was taken as a proxy for the 
mean. Weighted estimates were, then, produced by using random-effects meta-analysis of rates 
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correction was applied. I2 index was produced as well along with its p-value in order to assess 
overall heterogeneity across studies. All tests were considered statistically significant at p<0.05. 
Analyses were performed with Meta-XL v.5.3 (EpiGear International Pty Ltd.).
Results
A total of 624 articles were identified. Thereof, 173 duplicates were eliminated. All remaining 
abstracts were screened and 33 articles were excluded due to non-human, ex vivo character of the 
study or a language other than English, German or French. 85 letters to the editor, reviews or 
comments were excluded. Full-text assessment of 322 records (11 without full-text access) 
resulted in 30 eligible articles by exclusion of 292 articles according to the inclusion and exclusion 
criteria declared above in this article (Figure 1).
Study characteristics
The 30 included, predominantly retrospective, observational single center studies from Australia, 
Europe, The Americas and Asia published between 2000 and 2018 represented a time period from 
1914 to 2017 with a total of 1340 cases of nail apparatus melanoma. The number of patients per 
study varied between 2 and 157. 9 studies were restricted to NAM in situ 31,33–39 or minimally 
invasive (<0.5mm) melanoma.20
Details about gender distribution were available in 28 studies and showed a male/female ratio 
between 0.3-2.5:1.10,19,34–43,20,44–51,22,26,29–33 Information on population age was given in 28 studies 
with a reported average age between 41.1 and 67 years (age range: 5-94 years).15,19,34–40,45–
47,20,48,50–52,22,26,29–33 818 of the NAM were located on the hand and 522 lesions on the foot.
Pathology
Tumor thickness was reported in 29 studies. Mean Breslow values were available from 12 studies 
with unselected tumor thicknesses and ranged from 0.82 to 8.70 mm. 22,26,50,52,30,40,41,43,45,46,48,49 
Ulceration status was mentioned with rates between 8.3% and 70.8% in 13 
studies.10,19,45,46,49,22,26,29,32,41–44 Sentinel lymph node biopsy (SLNB) was performed in 12 studies 
and positivity rates varied between 0% and 30.6%.10,19,50,51,26,30,42–44,46,47,49 Predominant 
histogenetic melanoma subtypes were acral lentiginous melanoma, nodular melanoma and 
superficial spreading melanoma.10,19,41,42,46,20,22,26,29–31,33,34 Application of immunohistochemistry 
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38,40,49,50 Investigation of molecular mutations in NAM was uncommon. Only one of the included 
studies assessed BRAF V600E, NRAS and cKIT mutations.19
Treatment
Wide local excision
A non-amputational surgical approach was chosen in 403 cases (30.0%). 17 studies reported 
performance of “en bloc” wide local excision including the distal pulp of the digit, proximal and 
two lateral nail folds.20,31,43,45,47–49,52,32–37,39,40 Two studies reported “extended en bloc” or 
“functional surgery” excision through additional amputation of the most distal part of the distal 
phalanx.29,38,44 
Applied lateral and proximal safety excision margins from the nail plate or clinically apparent 
lesion were inconsistent and ranged from 5-10mm for both in situ 20,31,33,35,45,47,49–51 and invasive 
melanomas 32,45,47–49,52 or were indistinct with 3-5mm or “wide” or “generous”. 43 Deep margin 
resection included 31,32,39,47,49,52 or excluded 20,29,35,36,38,40,50,51 the periosteum.
Besides healing by secondary intention 33,34,36,39,48 different defect reconstruction techniques were 
chosen. In the most frequent approach, a full-thickness skin graft (FTSG) was harvested from 
forearm,31 lower abdomen,50 groin,47 inner arm 20,39 or thigh.39 Other sporadically used defect 
covering techniques were flag, 35,52 Foucher, 52 cross-finger 38 or interpolated flaps.50 
Reconstruction could be immediate 20,31,39,49,52 or delayed.31,50,52 
Amputation
In 700 cases (52.5%), amputation was the treatment of choice and consisted in the partial or full 
resection of one or more phalanges and/ or metacarpal or metatarsal bones. Reported levels of 
amputation were (ranging from distal to proximal) the partial amputation of the distal phalanx, 
distal interphalangeal joint, median phalanx, proximal interphalangeal joint, metacarpo-
/metatarsophalangeal joint, metacarpal/metatarsal and carpometacarpal joint. 10,15,43–
46,48,50,51,19,29,30,32,33,38,41,42 
Functional outcome
Conservative treatment followed by skin reconstruction or secondary intention healing resulted in 
the  majority in high patient satisfaction with mostly good cosmetic outcome.31,33,36,45,47,50 
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reduced pulp mobility mostly resolved within maximally one year postoperatively with minimal 
influence on quality of life.31,36,45,50 Lee et al.47 demonstrated significant superior functional 
assessment scores in patients treated by WLE compared to amputation. Persistent pain was 
reported as a surgery-related symptom.33,36,50
Adjuvant therapies
Only few studies included in this systematic review mentioned adjuvant approaches in metastatic 
NAM. The use of chemotherapeutical agents such as Dacarbazine41 or Cytoxan51 was reported in 
two studies. Immunotherapies with Interferon alpha41 or Ipilimumab51 were described. One study 
mentioned the administration of irradiated autologous melanoma cells in 70 patients.15 
Prophylactic isolated limb perfusion was applied in designated patients in a time period before 
abandoning the procedure due to absent survival improvement.42
Prognosis
Mortality and progression rates were analyzed by using meta-analysis and the overall estimates 
were a weighted average of all study rates. Based on 18 studies included in this analysis, the final 
pooled mortality rate (Figure 2) was 4.6 x 100 patient-years (95% CI: 2.7, 6.8), which is 
equivalent to an estimated 5-year cumulative survival of 77.0%. Yet, two studies 19,41 showed 
higher mortality rates.
Regarding the progression-rate (Figure 3), the overall pooled estimate, based on data of 17 studies, 
was 6.3 x 100 patient-years (95% CI: 4.1, 8.9), with an estimated 5-year cumulative progression-
free survival of 68.5%. Only the study of Reilly et al.19 showed a higher progression rate (25.0 x 
100 patient-years). 
For both outcomes, the overall heterogeneity across studies was significantly high (>90%, 
p<0.001). There was a visible trend towards lower rates over time, although this was not 
statistically significant.
Associated factors
Seven authors performed analysis of factors potentially influencing DFS (disease-free 
survival).19,26,29,30,32,42,43 Tumor thickness,26,29,30,32 tumor stage,42 ulceration,26 mitoses,42 positive 
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respective groups. In contrast, the level of amputation was not significantly associated with 
decreased DFS. 29,30,42
Analysis of factors possibly related to survival outcome was performed in ten reports. 
10,15,19,22,26,30,41,42,44,48 Tumor stage 10,15,22,42 seemed related with overall or disease-specific survival 
in four study populations. Three out of five studies 10,15,22,26,30 showed significant association 
between tumor thickness and survival in their respective samples upon analysis. Ulceration was 
negatively associated with survival outcome in three of four studies.10,15,19,26 In the study by Nunes 
et al.,26 positive SLNB was found to correlate with a worse prognosis. In addition, Bormann et 
al.41 found a significant correlation between concomitant trauma in NAM and lower survival rates. 
The level of resection was not shown to influence survival outcome in any of the studies. 30,42,48
Discussion
Few existing literature has reported the way of treatment and oncologic prognosis of nail 
apparatus melanoma. In this systematic review, we aimed to outline open issues regarding surgical 
procedures and outcome of this rare melanoma subset.
Sentinel lymph node biopsy of melanomas provides important prognostic information and the 
outcome provides additional information for the management and treatment of the patient.53 
Positive sentinel rates appear high in tumors of the nail apparatus and are discussed to reflect the 
locally advanced nature of the primary lesions at first encounter with a professional or a high 
number of patients undergoing SLNB.10,19,42,43 Yet, a correlation between tumor thickness and 
sentinel positivity has not been demonstrated.19 Additionally, the appropriate moment for sentinel 
examination remains debated. Unsuitable biopsy techniques can lead to substantial discrepancy 
between initial tumor thickness on the obtained specimen and the postoperative Breslow thickness 
after final resection.19,43 As such divergence affects the subsequent diagnostic management of the 
patient (such as SLNB) complete excisional biopsy should always be applied.
However, existing data on the application of SLNB in NAM is a rarity and mostly of low evidence 
making definitive conclusions impossible and underscoring the need for SLNB-directed research 
trials in NAM. While surgery is generally seen as the most adequate therapeutic approach, clear 
orientation guidelines are absent for the surgical treatment of NAM and current standards for 
primary cutaneous melanoma are of limited use in the nail area.45,51,54–58 Thus, the radicality of 
resection differed widely between all reviewed studies. Neither varying levels of 
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The debate about oncologic safety, and thus the most favorable level of resection, goes along with 
the unique anatomy of the nail apparatus,15,40,49 the short matrix-to-bone distance49,59 and the 
frequently irregular borders of NAM due to scattered proliferating melanocytes.10,20,33,34,38,39 Both 
present a challenge with regard to the potential risk of bone involvement and sufficient excision 
margins, in particular, when keeping in mind the observed difference between initial biopsy and 
final postoperative tumor thickness.10,19,43,50 Furthermore, these obstacles combined with varying 
size and site of the melanoma within the nail apparatus33 might explain inconsistent surgical 
margins20,33,45,49 and variable implementation of periosteal resection20,31,32,36,49,52 during WLE 
throughout literature and may represent an ongoing ambiguity. Further, subsequent amputation has 
been observed in individual cases with in situ melanoma due to positive excision margins.43
However, some authors have suggested WLE as a reasonable approach for in situ33,43 and 
minimally invasive lesions.20,45,49 While keeping oncologic safety the unconditional priority, 
preservation of functionality through conservative en bloc surgery should be aimed in non-
invasive lesions. In our opinion, the earliest possible confirmation of a suspected NAM by biopsy 
seems fundamental to allow consideration of a more or less radical surgical method. Yet, we feel 
that investigation of a larger population might help to address this debated topic soundly. Above 
all, clinical examination and dermoscopy for life is crucial regardless of the chosen surgical 
approach.
Besides discussion about the best treatment strategy, NAM is generally accepted to have a poor 
prognosis. However, only small study populations have been examined. To our knowledge, our 
data is the first to present pooled survival and progression rates. Interestingly, progression rates 
seem roughly consistent despite the high heterogeneity of studies whereas survival analysis 
presented a more diverse result. Two studies observed higher mortality rates, which might be 
explained by the increased average tumor thickness (4.5mm19 and 3.5mm41) in these reports 
compared to others.
There may be a risk of referral bias when assessing studies on NAM as all populations included 
herein were seen in specialized centers. However, this rare melanoma in the nail region demands 
expertise and thus the vast majority of cases may be treated within such setting. Small sample 
sizes and selected populations limit the applicability of our findings because the reported results 
vary considerably across studies. Additionally, due to the scarcity of NAM patients it cannot be 









Nevertheless, we could demonstrate an estimated trend from existent reports on survival and 
highlight the most important gaps of evidence in order to target future research.
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Figure Legends 
Figure 1 – Flow of information during the different phases of systematic review. 
Figure 2- Forest plot of mortality rates for all studies included 
Mortality and progression rates were analyzed by using meta-analysis and the overall estimates were a weighted average of all study rates. Based on 
18 studies included in this analysis, the final pooled mortality rate was 4.6 x 100 patient-years (95% CI: 2.7, 6.8), which is equivalent to an estimated 
5-year cumulative survival of 77.0%. 
Figure 3- Forest plot of mortality rates for all studies included 
Regarding the progression-rate, the overall pooled estimate, based on data of 17 studies, was 6.3 x 100 patient-years (95% CI: 4.1, 8.9), with an 
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2. (ungual* adj2 melanom*).ab,kw,ti. 
3. (subungual* adj2 melanom*).ab,kw,ti. 
4. (nail* adj2 melanom*).ab,kw,ti. 
5. (("nail bed" adj2 melanom*) or ("nail matrix" adj2 melanom*)).ab,kw,ti. 
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9. exp Nail Diseases/ 
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11. exp Skin Neoplasms/ 
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This article is protected by copyright. All rights reserved










































54 36/10 4 98 (77/21) 1/0 31 44 105 70
NAM on 
hands 





94 61/16 NM NM 0/157 26 33 35.1 35.1
Goettmann 
et al., 2018






NM NM 12 9 (NM) 0 1 5 73 31.2
Flores-Terry 




1 NM 5 2 (2/0) 0 1 1 46 46





2 17/2 41 0 0 0 2 31 22.5 WLE
Ogata D et al., 
2017
151 NM 86 NM 36 113 (51/57) 0/2 27 29 113 113










This article is protected by copyright. All rights reserved
et al., 2017 0.3-18
Anda-Juarez 
MC et al., 
2016
15 in situ NM NM 15 0 0 0 0 55.93 in situ





24 15/3 30 9 (9/0) 0 7 10 60 67
Duarte AF 
et al., 2015



























































NM 10/2 7 11 (5/6 0 3 1 34 15
NAM on 
hands















This article is protected by copyright. All rights reserved





NM 2/0 10 0 0 0 0 37.8 WLE
Neczyporenko 
F et al., 2014

























NM NM 7 0 0 0 0 45
WLE, 
<0.5mm
Andre J et al., 
2010





2 in situ NM NM 2 0 0 0 0 27
WLE,
 in situ








































































19 NM 0 32 (16/16) 1/0 21 17 53 53
Lazar et al., 
2005
9 in situ NM NM 9 0 0 0 0 50.4




































NM NM 14 0 0 4 4 92 67.1 WLE 
O'Leary JA 
et al., 2000
93 NM NM NM 0 93 0 43 62.4
NM: Not mentioned, *AJCC 2001, **AJCC2017, †median, ‡ in situ included
A
cc
ep
te
d 
A
rt
ic
le
jdv_16121_f1.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
jdv_16121_f2.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
jdv_16121_f3.tif
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
